FDA rejects Genentec's cancer drug label expansion

3 hours ago 1
World Cancer Day banner design with colorful ribbons for different types of cancer on a background and copy space in 3D illustration

Genentech, part of the Roche Group (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF), announced that the U.S. FDA has rejected its request to expand the use of its cancer drug Columvi.

The company had applied for approval to use Columvi in combination with chemotherapy

Recommended For You

More Trending News

Read Entire Article